Loading...
Loading...
- Illumina Inc ILMN reported Q3 revenues of $1.11 billion, +40% Y/Y, beating the consensus of $1.04 billion.
- Consolidated Product revenues were $978 million, while Service and other revenues were $130 million.
- "Illumina's financial results again exceeded expectations in the third quarter led by record shipments for both clinical and research," said Francis deSouza, CEO.
- Illumina's Q3 consolidated adjusted EPS was $1.45, beating analysts' consensus of $1.14 and higher than $1.02 posted a year ago.
- The adjusted gross margin improved to 71.2% from 67.4% last year.
- The company finished Q3 with $1.08 billion in cash and cash equivalents and $185 million in short-term investments.
- Guidance: Illumina expects FY21 revenue growth of approximately 36%, compared with the prior expectation of 32% - 34%.
- It forecasts adjusted EPS of $5.50 - $5.60 (consensus $5.73), including dilution of approximately $1.00/share from Grail's adjusted operating loss and incremental dilution of $0.15/share from the 9.8 million shares issued to fund the acquisition.
- Related: EC Adopts Interim Measure, Tells Grail To Work On Alternatives To Illumina Deal.
- Price Action: ILMN shares closed 0.54% higher at $421.83 on Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in